Physician profile
Chang Xia
NPI 1114187549
$4,963.23
in general payments reported to CMS, 2019-2025
59 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $329 · 2021: $543 · 2022: $949 · 2023: $1,106 · 2024: $1,087 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,597.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $559.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $446.47 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Genentech USA, INC. | $411.97 | 2019-2025 | Perjeta, Polivy, Tecentriq |
| Celgene Corporation | $357.42 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $242.76 | 2019-2022 | |
| Janssen Biotech, INC. | $232.02 | 2019-2025 | Rybrevant, Imbruvica, Erleada |
| Merck Sharp & Dohme LLC | $179.61 | 2019-2025 | Keytruda, Welireg |
| Genzyme Corporation | $164.13 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $152.85 | 2021-2024 | Ultomiris |
| G1 Therapeutics, INC. | $136.54 | 2022-2023 | Cosela |
| Incyte Corporation | $130.96 | 2021-2025 | Monjuvi, Pemazyre, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $115.80 | 2020-2024 | |
| Adaptive Biotechnologies Corporation | $103.10 | 2022-2024 | Clonoseq |
| Blueprint Medicines Corporation | $97.17 | 2020-2023 | Ayvakit |
| Pfizer INC. | $92.97 | 2019-2024 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chang Xia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.